Sacramento News-Online

Intrahepatic Cholangiocarcinoma Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Taiho Oncology (LYTGOBI/futibatinib), GENFIT (GNS5611), Basilea (Derazantinib)

 Breaking News
  • No posts were found

Intrahepatic Cholangiocarcinoma Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Taiho Oncology (LYTGOBI/futibatinib), GENFIT (GNS5611), Basilea (Derazantinib)

October 05
22:32 2022
Intrahepatic Cholangiocarcinoma Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Taiho Oncology (LYTGOBI/futibatinib), GENFIT (GNS5611), Basilea (Derazantinib)
Delveinsight Business Research LLP
As per DelveInsight, the Intrahepatic Cholangiocarcinoma market size shall increase in the coming years owing to the launch of upcoming therapies and intense research and development (R&D) activities by pharma and biotech giants in the therapeutics segment.

As per DelveInsight’s assessment, globally, about 20+ key pharma and biotech companies are working in the Intrahepatic Cholangiocarcinoma therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

DelveInsight’s “Intrahepatic Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Intrahepatic Cholangiocarcinoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Intrahepatic Cholangiocarcinoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Intrahepatic Cholangiocarcinoma Market

Intrahepatic Cholangiocarcinoma: An Overview

Intrahepatic Cholangiocarcinoma (ICCA) originates from the liver parenchyma beyond the second-order bile ducts and belongs to a family of aggressive cholangiocarcinomas, a rare and heterogeneous malignant neoplasm with an epithelial cell of the biliary duct and has the histologic and biochemical features of cholangiocyte differentiation.

Receptor tyrosine kinases such as IL-6 receptor, c-MET, and the EGFR family members ERBB2 and ERBB1 are key signaling pathways in ICCA. Aberrant activation of tyrosine kinases receptor causes constitutive activation of downstream signaling cascades (i.e., JAK/STAT3, PI3K/Akt, ERK1/2, and p38MAPK), resulting in dysregulation of cell senescence, cell cycle regulation and proliferation, and apoptosis. 

Intrahepatic Cholangiocarcinoma Market Key Facts

  • As per DelveInsight, the total incident population of Intrahepatic Cholangiocarcinoma in the 7MM was 10,289 in 2017. Among all the countries, the estimates showed a higher incidence of ICCA in the United States in 2017.

  • Among the EU5 countries, Germany had the highest incident population of Intrahepatic Cholangiocarcinoma with 2,459 cases, followed by the United Kingdom and Italy. Besides, Spain had the lowest incident population.

  • As per the DelveInsight, Japan had 2,315 incident cases of Intrahepatic Cholangiocarcinoma in 2017.

  • The estimates suggest that a higher number of ICCA cases were found in the age group 70–79 years in the US; however, EU5 and Japan showed higher incident cases in the age group of 80 and above.

Intrahepatic Cholangiocarcinoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Intrahepatic Cholangiocarcinoma market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Intrahepatic Cholangiocarcinoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Intrahepatic Cholangiocarcinoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Intrahepatic Cholangiocarcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Intrahepatic Cholangiocarcinoma market or expected to get launched during the study period. The analysis covers Intrahepatic Cholangiocarcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Intrahepatic Cholangiocarcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Latest Developments in the Intrahepatic Cholangiocarcinoma Therapeutics Market

On September 30, 2022, Taiho Oncology, Inc. announced that the US FDA had approved LYTGOBI® (futibatinib) tablets for the treatment of adult patients with previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma (iCCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

On September 13, 2022, GENFIT (Nasdaq and Euronext: GNFT) announced that the US FDA had granted Orphan Drug Designation to GNS5611 (ezurpimtrostat), a novel clinical-stage autophagy/PPT1 inhibitor, for the treatment of cholangiocarcinoma.

Learn How Intrahepatic Cholangiocarcinoma Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-market

Intrahepatic Cholangiocarcinoma Therapeutics Analysis

There are approx. 20+ key companies which are developing therapies for Intrahepatic Cholangiocarcinoma. Currently, Basilea Pharmaceutica has its Intrahepatic Cholangiocarcinoma drug candidates in the most advanced stage of clinical development.

Globally, some of the key companies in the Intrahepatic Cholangiocarcinoma Therapeutic Market include:

Basilea Pharmaceutica, AstraZeneca,  Delcath Systems Inc., Jiangsu HengRui Medicine Co., Ltd., Syndax Pharmaceuticals, Hutchison Medipharma Limited, Medivir,  Newish Technology (Beijing) Co., Ltd.,  Relay Therapeutics, Inc., Exelixis, Forma Therapeutics, Inc., Xencor, Inc., Zymeworks, Bristol-Myers Squibb, RedHill Biopharma Limited, Genoscience Pharma, Kinnate Biopharma, Taiho Oncology, Inc., Sirtex Medical, and many others.

Intrahepatic Cholangiocarcinoma Drugs Covered in the report include:

  • Derazantinib (Basilea Pharmaceutica)

  • Durvalumab (AstraZeneca)

  • Melphalan Hydrochloride

  • Yeliva 

And many others

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –

https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Intrahepatic Cholangiocarcinoma Competitive Intelligence Analysis

4. Intrahepatic Cholangiocarcinoma Market Overview at a Glance

5. Intrahepatic Cholangiocarcinoma Disease Background and Overview

6. Intrahepatic Cholangiocarcinoma Patient Journey

7. Intrahepatic Cholangiocarcinoma Epidemiology and Patient Population (In US, EU5, and Japan)

8. Intrahepatic Cholangiocarcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Intrahepatic Cholangiocarcinoma Unmet Needs

10. Key Endpoints of Intrahepatic Cholangiocarcinoma Treatment

11. Intrahepatic Cholangiocarcinoma Marketed Products

12. Intrahepatic Cholangiocarcinoma Emerging Drugs and Latest Therapeutic Advances

13. Intrahepatic Cholangiocarcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Intrahepatic Cholangiocarcinoma Market Outlook (In US, EU5, and Japan)

16. Intrahepatic Cholangiocarcinoma Access and Reimbursement Overview

17. KOL Views on the Intrahepatic Cholangiocarcinoma Market

18. Intrahepatic Cholangiocarcinoma Market Drivers

19. Intrahepatic Cholangiocarcinoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Castrate-Resistant Prostate Cancer (CRPC) Market

“Castrate-Resistant Prostate Cancer (CRPC) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Castrate-Resistant Prostate Cancer (CRPC) Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/